Get the Daily Brief
Latest Biotech News
Structures of bacterial RNR control point to new antibiotic strategies
Researchers mapped the structural mechanisms by which bacteria regulate ribonucleotide reductase (RNR) activity via the specialized transcriptional regulator NrdR, revealing bacterial‑specific...
Disorganized LNPs release RNA more efficiently — single‑particle study
A University of Copenhagen team reported that amorphous lipid nanoparticles (LNPs) release therapeutic cargo more efficiently than highly organized particles, based on a high‑throughput...
Functional electrophysiology probe aims to improve organoid screening
Diagnostic Biochips introduced a neural probe platform designed to record functional electrophysiology from brain organoids at scale, a capability the company says will improve early‑stage...
Element unveils Vitari — $100 30X genome in 36 hours
Element Biosciences launched Vitari, a high‑throughput sequencing platform the company says can deliver 3 terabases per paired‑end 150 bp run in 36 hours and sequence a 30X human genome for...
Stanford reports universal intranasal vaccine protecting mice across respiratory threats
Stanford Medicine reported a preclinical intranasal vaccine that protected mice against multiple respiratory viruses, bacterial pathogens and even an allergen by combining innate and adaptive...
Grail’s Galleri misses NHS goal — stock tumbles
Grail disclosed that its large NHS-Galleri multicancer early detection (MCED) trial failed to meet the study’s primary endpoint, triggering a sharp sell-off in the company’s shares. The trial, run...
FDA formalizes single pivotal-trial default — approval bar shifts
FDA leaders have signaled a formal shift: the agency will default to accepting one well-controlled, adequately run pivotal trial as sufficient evidence for approval, augmented by “confirmative...
Japan backs two iPSC therapies: first-in-world approvals near
Japan’s regulatory subcommittee recommended conditional, time-limited approvals for two induced pluripotent stem cell (iPSC)-derived therapies — Amchepry (raguneprocel) and Reheart — positioning...
Danaher agrees $10B Masimo takeover — diagnostics consolidation accelerates
Danaher announced a cash acquisition of Masimo valued at roughly $9.9–$10 billion to expand its acute-care diagnostics and patient-monitoring portfolio. The deal consolidates pulse oximetry and...
Guardant doubles down on screening — acquires MCED startup, raises guidance
Guardant Health said it expects substantial growth in its Shield screening business for 2026 and disclosed an acquisition of MCED startup MetaSight Diagnostics for $59 million upfront plus...
Altesa raises $75M to advance antivirals — Giroir leads Series B
Altesa BioSciences closed a $75 million Series B to advance vapendavir, an oral antiviral targeting rhinoviruses, into larger clinical testing for respiratory disease and COPD exacerbation...
Novartis commits $100M to macrocycle startup — peptide frontier expands
Novartis committed $100 million to Unnatural Products to advance macrocyclic peptide technology aimed at previously undruggable targets, joining existing collaborations the startup holds with...
FDA reverses Moderna refusal — agency turmoil lands in Washington
The FDA reversed an initial Refuse‑to‑File decision and agreed to review Moderna’s mRNA influenza vaccine application after a Type A meeting between agency staff and the company. The U‑turn...
AI to lab-in‑loop: Insilico, Lilly and rapid evolution reshape R&D
Insilico Medicine and Lilly published a framework envisioning a fully autonomous “prompt-to-drug” pipeline integrating generative AI across design, synthesis, and testing. Parallel advances are...
High‑throughput sequencing race heats up — Element’s Vitari and new platforms
Element Biosciences unveiled Vitari, a high‑throughput sequencer that promises $100 30× genomes by delivering 3 Tb per run; at the same time vendors are launching spatial and single‑cell platforms...
Grail’s Galleri misses NHS endpoint — shares collapse
Grail reported that its NHS‑Galleri multicancer early detection (MCED) trial did not meet the primary endpoint of a statistically significant reduction in late‑stage (Stage III–IV) cancers. The...
FDA makes single pivotal trial the default — NEJM chiefs explain
Top FDA officials wrote in the New England Journal of Medicine that the agency will adopt a single‑pivotal‑trial default for drug approvals, signalling an explicit policy shift from the...
Japan backs two iPSC therapies under early‑approval pathway
Japan’s regulatory advisory body recommended conditional, time‑limited approvals for two iPSC‑derived therapies: Amchepry (raguneprocel) and Reheart, positioning them to become the first iPSC...
Altesa closes $75M Series B to push antivirals into COPD trials
Altesa BioSciences closed a $75 million Series B to advance vapendavir, an oral antiviral that targets rhinovirus, into larger COPD‑focused clinical testing. The round, led by Forbion with...
Korsana emerges with $175M to pursue Alzheimer’s brain‑shuttle antibody
Korsana Biosciences launched from stealth with $175 million to develop KRSA‑028, an antibody engineered to cross the blood‑brain barrier and clear amyloid plaques. The Boston company’s financing...